1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsAdvanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH). This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) - Oncology News, Insights, Stories by OncoDaily Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) The National Cancer Institute (NCI) invites R33 grant applications to support advanced development and rigorous validation of novel molecular or cellular analysis technologies that offer transformative capabilities for cancer research, including basic biology, early detection, diagnostics, treatment, and disparities research .
U.S. and foreign organizations of any type, including higher education institutions, nonprofit and for-profit entities (small businesses and others), local/state/federal governments, and tribal organizations. Foreign components of U.S. organizations and standalone foreign organizations are eligible. Applicant institutions must have required registrations (SAM, UEI, NCAGE if applicable, eRA Commons, Grants.
gov) completed prior to submission . PD(s)/PI(s) must have eRA Commons accounts; organizational Signing Officials require separate accounts. Multi-PD/PI applications are allowed under NIH’s MPI policy.
Estimated 10 awards in FY2026, total budget ~4. 3 M USD. Up to 300,000 USD direct costs per year; project period up to 3 years.
No clinical trials allowed. Funds may cover technology development, validation experiments, performance measure assessments, and related personnel, supplies, and core costs; must follow NIH cost principles .
Letter of Intent: 30 days before application due date Application Due Dates: April 4, 2025 and October 3, 2025 (by 5:00 PM local applicant time) Scientific Merit Review: July 2025 (first cycle), February 2026 (second cycle) Earliest Start Dates: December 2025 and July 2026 respectively . Where to Go for Further Information: Prepare and submit applications via NIH ASSIST, Grants. gov Workspace, or institutional S2S.
Funding Opportunity Number: RFA-CA-25-002 . Contact Kelly Crotty, Ph. D.
(NCI) at kelly. crotty@nih. gov for scientific inquiries; GrantsInfo@nih.
gov for application guidance; Grants. gov Support at support@grants. gov for system help.
exploratory developmental grant Global fight against cancer MD Anderson Cancer Center Dana-Farber Cancer Institute European Cancer Organisation American Society of Clinical Oncology National Cancer Institute Memorial Sloan Kettering Cancer Center European School of Oncology The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes. Manage {vendor_count} vendors The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes.
Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you. The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes. Manage {vendor_count} vendors
According to the current listing, eligibility includes: Academic institutions, nonprofit organizations, and other entities engaged in biomedical research. Confirm the full requirements in the official notice before applying.
The current listing shows up to $300,000 direct costs per year for up to 3 years. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article